# Multicenter Randomized Double-blind Placebo-controlled Study to Investigate Azvudine in Symptomatic Adults With COVID-19 at Increased Risk of Progressing to Severe Illness

> **NCT05689034** · PHASE2,PHASE3 · RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 1096 (estimated)

## Conditions studied

- COVID-19 Respiratory Infection

## Interventions

- **DRUG:** Azvudine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05689034
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-19
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 1096 (ESTIMATED)
- **Last updated:** 2024-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05689034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05689034, "Multicenter Randomized Double-blind Placebo-controlled Study to Investigate Azvudine in Symptomatic Adults With COVID-19 at Increased Risk of Progressing to Severe Illness". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05689034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*